Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572)
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Who can join: Review the eligibility criteria below.
Location: University of Chicago — Chicago, Illinois
Age range: 13 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- University of Chicago — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of North Carolina — Chapel Hill, North Carolina
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- University of Cincinnati — Cincinnati, Ohio
- The Ohio State University — Columbus, Ohio
- MD Anderson Cancer Center — Houston, Texas
- University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (206) 335-3820
Email: yu@newavepharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Hodgkin Lymphoma
- Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) — Duarte, California
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma — Tucson, Arizona
- TmCD19-IL18 in CD19+ Cancers — Philadelphia, Pennsylvania
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma — Cincinnati, Ohio
- Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas — Iowa City, Iowa
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies — Cleveland, Ohio
Explore by condition: All Non Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.